<DOC>
	<DOCNO>NCT00360594</DOCNO>
	<brief_summary>Acamprosate approve Food Drug Administration ( FDA ) treatment alcoholism . The purpose study see initiate acamprosate early alcohol detoxification instead wait detoxification complete effect course detoxification , adverse event detoxification , drop rate rehabilitative treatment phase , overall efficacy acamprosate alcohol dependence plan receive least two month rehabilitative pharmacotherapy acamprosate .</brief_summary>
	<brief_title>Acamprosate Initiated During Alcohol Detoxification</brief_title>
	<detailed_description>Biphasic clinical trial , consist randomize , double-blind , placebo-controlled detoxification treatment phase ( DP ) , follow 9-week open-label rehabilitative treatment phase ( RP ) .</detailed_description>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Inclusion Criteria Detoxification Treatment Phase 1 . Males female age 18 70 year old . Subjects age 70 year old include discretion PI , expectation subject comprise 5 % subject . 2 . Diagnosis current alcohol dependence accord DSMIV criterion [ DSMIV criterion determine utilize Mini International Neuropsychiatric Interview ( MINI ) ] . 3 . If necessary , medically detoxified outpatient setting , determine medical clinician . 4 . Meets follow drinking criterion , measure TLFB : a. report minimum 48 standard alcoholic drink ( avg 12 drinks/wk ) consecutive 30day period 90day period prior start pharmacotherapy , b. 2 day heavy drinking ( defined 5 drink per day male 4 drink per day female ) within 30 day start pharmacotherapy treatment c. drink within 48 hour intake/screening visit CIWA score equal great 3 . 5 . Speaks , understand print English . 6 . Gives write informed consent . Exclusion Criteria Detoxification Treatment Phase ( DP ) 1 . Subjects mandate treatment base upon legal decision condition employment . 2 . Subjects evidence substance dependence alcohol nicotine dependence . 3 . Subjects psychosis dementia time initial evaluation . 4 . Female Subjects pregnant lactating , female Subjects child bear potential use acceptable method birth control . Acceptable method birth control include : tubal ligation , barrier ( diaphragm condom ) spermicide , intrauterine progesterone contraceptive system , levonorgestrel implant , medroxyprogesterone acetate contraceptive injection , oral contraceptive . 5 . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) outside normal limit clinically unacceptable Principal Investigator . EKG first degree heart block , sinus tachycardia , leave axis deviation , nonspecific ST T wave change allow ; liver function test [ LFTs ] &lt; 5 x ULN acceptable ) , Subjects impaired renal function indicate corrected creatinine clearance 80 ml/min/70 kg determine modify Cockcroft equation ( CDC , 1986 ) . 6 . Subjects positive urine drug screening ( cocaine , amphetamine , opiate , barbiturate , benzodiazepine ) 7 . Subjects disease gastrointestinal tract , liver kidney could result possibility alter metabolism excretion study drug . As possible enumerate many condition might impair absorption , metabolism , excretion , investigator guide evidence : History major gastrointestinal tract surgery ( gastrectomy , gastrostomy , bowel resection , etc . ) history active peptic ulcer chronic disease GI tract , ( ulcerative colitis , regional enteritis , gastrointestinal bleeding ) . 8 . Current unstable heart disease . 9 . Known hypersensitivity acamprosate . 10 . Subjects take psychotropic drug ( e.g. , antidepressant , anxiolytic , antipsychotic , naltrexone , disulfiram , modafinil , stimulant anticonvulsant ) exception oxazepam 11 . Subjects receive formal psychotherapy 12 . Subjects participate investigational drug trial within 30 day prior study . 13 . Subjects AIDS serious illness may require hospitalization study . Inclusion Criteria PostDetoxification Rehabilitative Treatment Phase ( RP/Phase 2 ) OpenLabel Acamprosate 1 . Has take least 5 day acamprosate placebo directly prior initiate openlabel acamprosate . 2 . Successfully complete , within 14day period , outpatient detoxification . Successful completion detoxification define score 1 low Clinical Institutes Withdrawal Assessment Alcohol ( CIWA ; Shaw et al. , 1981 ) , least 3 consecutive day abstinence . 3 . Has reduce medication take specifically detoxification ( applicable ) , i.e. , oxazepam 45 mg within 24hour period prior postdetoxification rehabilitative treatment phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>alcoholism</keyword>
</DOC>